CAF-mediated compartmentalized dual POSTN–ITGB8 axis drives Osimertinib resistance in lung adenocarcinoma
Journal of Pharmaceutical Analysis · 2026-06 · 101689
DOI: 10.1016/j.jpha.2026.101689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-06. Verfasst von Jiaming Cao und 8 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cao, J., Liu, Y., Chen, J., Li, X., Yin, Z., Xue, X., Chen, B., Zhou, B., & Zheng, C. (2026). CAF-mediated compartmentalized dual POSTN–ITGB8 axis drives Osimertinib resistance in lung adenocarcinoma. Journal of Pharmaceutical Analysis, 101689. https://doi.org/10.1016/j.jpha.2026.101689
Vancouver
Cao J, Liu Y, Chen J, Li X, Yin Z, Xue X, et al. CAF-mediated compartmentalized dual POSTN–ITGB8 axis drives Osimertinib resistance in lung adenocarcinoma. Journal of Pharmaceutical Analysis. 2026:101689. doi:10.1016/j.jpha.2026.101689
BibTeX
@article{Cao2026,
author = {Cao, Jiaming and Liu, Yibing and Chen, Junting and Li, Xuelian and Yin, Zhihua and Xue, Xiaoxia and Chen, Bonan and Zhou, Baosen and Zheng, Chang},
title = {CAF-mediated compartmentalized dual POSTN–ITGB8 axis drives Osimertinib resistance in lung adenocarcinoma},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
pages = {101689},
doi = {10.1016/j.jpha.2026.101689}
}
EUVIMED